If you’re experiencing a continuous peeling of the skin on the palms of your hands or the soles of your feet, you may be dealing with Acral Peeling Skin Syndrome (APSS). It is a rare but important skin disorder to understand. We’ll walk through everything you need: what APSS is, how to recognize it, what the latest research shows, how it’s properly diagnosed and managed, and how genetic testing may play a role.

Researchers estimate that this rare disease affects less than 1 in a million people globally. Did you know? According to recent updates on PubMed and JIDOnline, genetic mutations in the TGM5 or CSTA genes are responsible for most cases of APSS. Yes, these genes are the classic example of autosomal recessive skin peeling syndrome. In this guide, we’ll tell you everything you need to know about this rare condition and practical ways to manage it.

What Is Acral Peeling Skin Syndrome?

APSS is a genetic skin disorder in which the outermost layer of skin repeatedly peels off over the acral surfaces, for example, palms and soles. The term “acral” refers to the extremities, hands, feet, fingers, and toes. The name fits exactly where the peeling shows up. It’s sometimes called peeling skin syndrome type 2 because it corresponds to the localized acral form. It is frequently associated with the TGM5 or CSTA  genes.

Common Names:

• Peeling skin syndrome type 2
• Acral peeling skin disorder
• Localized deciduous skin
• Acral PSS (APSS)

Genetic Causes of Acral Peeling Skin Syndrome

APSS is inherited in an autosomal recessive pattern; both parents must carry the gene mutation for a child to be affected. Two key genes are involved:

1. TGM5 (Transglutaminase 5) Gene on Chromosome 15

• The TGM5 gene encodes transglutaminase-5, an enzyme crucial for the formation of the cornified cell envelope, which keeps skin layers bound together, and it is present on chromosome 15.
• Mutations in the transglutaminase-5 (TGM5) gene impair the enzyme that cross-links structural proteins (like loricrin, involucrin) in the skin barrier.
• It affects skin adhesion, causing superficial peeling of palms and soles.

For example, the well-studied mutation p.Gly113Cys completely abolishes enzyme activity in vitro.

2. CSTA (Cystatin A) Gene on Chromosome 13

• The CSTA gene present on chromosome 13 produces cystatin A, a protein that prevents excessive skin protein breakdown. Cystatin A protein acts as a “skin glue”, keeping the outer layers attached firmly.
• Less common but increasingly recognized. Mutations in CSTA (cystatin A) have been found in a small number of APSS-type cases.
• This mutation impacts skin barrier function and leads to localized peeling.

These genes play vital roles in maintaining the integrity of the epidermal barrier, which protects the body from environmental factors like heat, humidity, cold weather, sun exposure and more.

Did you know?

RPh Labs’ CLIA-accredited PGx testing can provide genetic insights not only for medications but also for inherited skin conditions, helping guide patient counseling and management.

Symptoms and Features of Acral Peeling Skin Syndrome

The symptoms of Acral Peeling Skin Syndrome vary in severity but are typically localized to the palms and soles. Common Signs include:

• Location: Superficial skin peeling on the hands and feet, but may also affect the limbs and arms.
• Onset of disease: In most cases, usually signs appear at birth or within the first few months of life. Rarely, milder cases might go undiagnosed until late childhood or adolescence (up to 15 years old)
• Triggering Factors: Peeling is often worsened by heat, humidity, moisture (like immersion in water), Friction or pressure, Mechanical trauma, and Seasonal changes. Painless exfoliation that may increase with heat or moisture.
• Skin biopsy (if done) will show cleavage between the stratum granulosum and stratum corneum.

These signs can flare up seasonally, as noted in Medical News Today reports. One practical example: A child with acral peeling skin disorder might struggle with playground activities if peeling worsens from sweat. But, it’s manageable with the right habits.

Note: For families concerned about inherited genetic conditions like Acral Peeling Skin Syndrome, understanding the role of prenatal and carrier genetic testing can be crucial. You can explore our detailed guide on Genetic Testing to learn how early screening helps identify such conditions.

Common Misdiagnoses and Why They Matter

That genetic difference changes everything, from genetic counseling to family-planning discussions. In APSS, there is no primary blistering disease. The skin peels rapidly, but typically no deeper blistering or scarring. Here are the conditions we really observed;

Condition	Key Differences	Why It Matters
APSS	Painless peeling on hands/feet; onset early; triggered by moisture/heat; autosomal recessive	Rare; may go undiagnosed
EBS‑loc	Blistering dominant pattern; autosomal dominant; more typical blister formation	Requires different counseling
Tinea/manuum/feet	Often itchy, fungal causes; positive lab/mycology	Treatable with antifungals—different path
Keratolysis exfoliativa	Peeling, but more due to callus/sloughing; not genetic	More benign, different management

Tip: If standard treatments for dermatitis or fungal infections fail, APSS should be considered. Genetic testing can confirm the diagnosis.

Did you know?

According to recent dermatology research published in the British Journal of Dermatology, APSS is often misdiagnosed as the localized form of Epidermolysis Bullosa Simplex – localized (EBS-loc). In fact, a landmark study identified 59 new APSS cases that had been previously labeled as EBS-loc.

Diagnosis of Acral Peeling Skin Syndrome

Diagnosing APSS requires careful evaluation because it shares symptoms with common skin conditions. Dermatologists may use:

• Clinical observation of hands and feet skin peeling disorder
• Family history of autosomal recessive skin peeling syndrome
• Genetic testing to identify TGM5 or CSTA mutations

RPh Labs’ PGx testing is primarily used to guide medication response. While it does not test for APSS directly, understanding your genetic profile can sometimes help clinicians interpret rare genetic conditions and support broader personalized counseling discussions.

Genetic Counseling:

Because APSS is autosomal recessive, if two parents are carriers, each child has a 25% chance of being affected. Confirming the genetic cause aids family planning.

Management and Treatment Options for APPS

Currently, there is no cure for APSS, but symptoms can be managed effectively. Key strategies include:

• Daily moisturizing to keep skin hydrated
• Avoid harsh soaps and chemicals to protect the skin barrier
• Gentle washing and exfoliation to prevent excessive peeling
• Regular dermatology check-ups
• Do not sit near the stove in winter
• Wear breathable gloves, shoes, and cotton socks
• Apply emollients like petroleum jelly or ceramide-based creams right after bathing.

Research and Future Outlook

According to JIDOnline, ongoing research is exploring potential gene-targeted therapies, which could offer personalized solutions for rare genodermatoses like APSS in the near future.

The studies on Acral Peeling Skin Syndrome are still in the development stage. Research into the role of TGM5 and CSTA mutations in destabilizing the epidermal structure and the possible use of gene therapy or molecular in vivo repair in the future is underway.

New developments in the field of genomic medicine and the study of rare diseases are making clinicians better comprehend rare genodermatoses such as APSS. Genetic testing is the best measure of identification of early disease so that diagnosis and care can be administered appropriately.

Conclusion:

APSS is a rare but real autosomal recessive genodermatosis causing peeling of the skin on acral surfaces (hands/feet). The most common gene involved is TGM5; less commonly CSTA. Newly reported mutations and modifiers are expanding our understanding. It is underdiagnosed and often misinterpreted as other conditions like EBS-loc or dermatitis. Recognizing the specific pattern is key. Management focuses on barrier protection, trigger avoidance and moisturization. While there’s no cure yet, but early care makes a big difference.

Disclaimer:

This blog is for educational use only and should not be used to make medical decisions. Some visuals are AI-generated for illustrative purposes only.

Frequently Asked Question